Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Intraperitoneal Perfusion Therapy of Endostar Combined with Platinum Chemotherapy for Malignant Serous Effusions: A Meta-analysis

  • Liang, Rong (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Xie, Hai-Ying (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Lin, Yan (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Li, Qian (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Yuan, Chun-Ling (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Liu, Zhi-Hui (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) ;
  • Li, Yong-Qiang (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University)
  • Published : 2016.01.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Malignant serous effusions (MSE) are one complication in patients with advanced cancer. Endostar is a new anti-tumor drug targeting vessels which exerts potent inhibition of neovascularization. This study aimed to systematically evaluate the efficacy and safety of intraperitoneal perfusion therapy of Endostar combined with platinum chemotherapy for malignant serous effusions (MSE). Materials and Methods: Randomized controlled trials (RCTs) on intraperitoneal perfusion therapy of Endostar combined with platinum chemotherapy for malignant serous effusions were searched in the electronic data of PubMed, EMBASE, Web of Science, CNKI, VIP, CBM and WanFang. The quality of RCTs was evaluated by two independent researchers and a meta-analysis was performed using RevMan 5.3 software. Results: The total of 25 RCTs included in the meta-analysis covered 1,253 patients, and all literature quality was evaluated as "B" grade. The meta-analysis showed that Endostar combined with platinum had an advantage over platinum alone in terms of response rate of effusions (76% vs 48%, RR=1.63, 95%CI: 1.50-1.78, P<0.00001) and improvement rate in quality of life (69% vs 44%, RR=1.57, 95%CI: 1.42-1.74, P<0.00001). As for safety, there was no significant difference between the two groups in the incidences of nausea and vomiting (35% vs 34%, RR=1.01, 95%CI: 0.87-1.18, P=0.88), leucopenia (38% vs 38%, RR=1, 95%CI: 0.87-1.15, P=0.99), and renal impairment (18% vs 20%, RR=0.86, 95%CI: 0.43-1.74, P=0.68). Conclusions: Endostar combined with platinum by intraperitoneal perfusion is effective for malignant serous effusions, and patient quality of life is significantly improved without the incidence of adverse reactions being obviously increased.

Keywords

References

  1. Barni S, Cabiddu M, Ghilardi M, et al (2011). A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol, 79, 144-53. https://doi.org/10.1016/j.critrevonc.2010.07.016
  2. Becker G, Galandi D, Blum HE (2006). Malignant ascites: systematic review and guideline for treatment. Eur J Cancer, 42, 589-97. https://doi.org/10.1016/j.ejca.2005.11.018
  3. Fan J, DU J, Wu J, et al (2015). Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma. Oncol Lett, 9, 822-8. https://doi.org/10.3892/ol.2014.2783
  4. Fei ZH, Yang XL (2011). Observation of clinical efficacy of endostar combined with cisplatin in the treatment for 32 cases of malignant ascite/pleural effusion patients. Zheiiane Practical Methane, 4, 266-7.
  5. Hang LM, Yu XL, Song H (2011). A comparision of between clinical efficacy intrapleural injection of cisplatin combined with Human recombinant endostatin and cisplatin alone in the treatment for malignant serous effusion. Chinese J Geriatric Care, 2, 44-5.
  6. Hang ZC, Wang F, Liu J (2013). The effect of rhendostatin combined with cisplatinum on patients with malignant pleural effusion. Chinese J Clin Pharmacol, 29, 587-9.
  7. Huang J (2010). Observation of clinical efficacy of endostar combined with cisplatin in the treatment of malignant pleural effusion. J Clin Med Practice, 14, 63-4.
  8. Huang L (2014). Clinical observation on endostar combined cisplatin in the treatment of non-small cell lung cancer malignant pleural effusion. Jilin Med, 19, 4308-9.
  9. Jiang B (2012). Clinical trials of endostar combined cisplatin for the local treatment of malignant pleural effusion. Qinghai University.
  10. Kang LY, Gao LM, Chao JL, et al (2013). Clinical observation on recombinant human endostain combined with cisplatinum intracavitary perfusion chemotherapy for malignant pleural effusion. Clinical Focus, 28, 1371-3.
  11. Kobold S, Hegewisch-Becker S, Oechsle K, et al (2009). Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist, 14, 1242-51. https://doi.org/10.1634/theoncologist.2009-0109
  12. Li JP, Gong KT, Zhu ZT, et al (2010). Recombinant human endostatin combined with cisplatin for malignant pleural effusion: a clinical study. China Pharmacy, 14, 1308-10.
  13. Li W, Ha MW, Ying NC, et al (2010). A clinical study of endostar combined with cisplatin intrapleural perfusion chemotherapy for non-small cell lung cancer with malignant pleural effusion. Shandong Med J, 8, 79-80.
  14. Li WY (2010). Observation of clinical efficacy of endostar intracavitary perfusion chemotherapy for malignant pleural effusion. J Med Forum, 32, 170-1.
  15. Ling Y, Yang Y, Lu N, et al (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 361, 79-84. https://doi.org/10.1016/j.bbrc.2007.06.155
  16. Liu J, Ye P, Su Z, et al (2015). Suppression of choroidal neovascularization by Endostar in rats. Mol Med Rep, 11, 3621-5. https://doi.org/10.3892/mmr.2014.3132
  17. Liu X, Wang LP (2012). Clinical observation of intracavitary chemotherapy of endostar combined with chemotherapy in the treatment of non-small cell lung cancer with malignant pleural effusion. J Basic Clin Oncol, 25, 233-5.
  18. Liu ZC, Cui EH, Wang B, et al (2011). Observation of clinical efficacy of human recombinant endostatin combined with carboplatin in the treatment for malignant pleural effusion. Zhejiang J Integrated Traditional Chinese Western Med, 11, 784-5.
  19. Lu HL (2014). Clinical observation on human recombinant endostatin combined with chemotherapy in the treatment of pleural effusion. Med Frontier, 14, 396-6.
  20. Lu N, Ling Y, Gao Y, et al (2008). Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med (Maywood), 233, 1013-20. https://doi.org/10.3181/0801-RM-7
  21. Ma Q (2014). Intrapleural and intraperitoneal combination therapy with bevacizumab and cisplatin for malignant pleural effusion and ascites. Dalian Medical University.
  22. Mao LW, Liao GQ, Wang HM, et al (2011). Observation of clinical efficacy of endostar combined with DDP on malignant bloody pleural effusion. Med J National Defending Forces Southwest China, 21, 723-5.
  23. Miao H, Kong FJ (2012). Clinical observation on radiofrequency thermotherapy combined with endostar and cisplatin in the treatment of malignant pleural effusion. Chinese Community Doctors, 14, 86-7.
  24. Shen Q, Gu AQ, Wu JY, et al (2012). Therapeutic observation of endostar combined with cisplatin on non-small cell lung cancer with malignant pleural effusion. J Clin Med Practice, 5, 29-31.
  25. Tamsma J (2007). The pathogenesis of malignant ascites. Cancer Treat Res, 134, 109-18.
  26. Verheul HM, Hoekman K, Jorna AS, et al (2000). Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist, 5, 45-50.
  27. Wei H, Qin S, Yin X, et al (2015). Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites. Oncol Lett, 9, 2694-700. https://doi.org/10.3892/ol.2015.3134
  28. Wu Y, Zheng Y, Shen Z, et al (2014). Endostar combined with radiotherapy increases radiation sensitivity by decreasing the expression of TGF-${\beta}1$, HIF-$1{\alpha}$ and bFGF. Exp Ther Med, 7, 911-6. https://doi.org/10.3892/etm.2014.1526
  29. Xiao F, Xiao ML, Tang YB, et al (2014). Clinical research on rhendostatin combined with cis-platinum on patients with maliganant peritoneal effusion. Chinese Foreign Health Abstract, 15, 43-4.
  30. Xu M, Huang H, Xiong Y, et al (2014). Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature. Oncol Lett, 8, 291-4. https://doi.org/10.3892/ol.2014.2087
  31. Xue H (2012). Clinical research on recombinant human endostain in the treatment of malignant ascite/pleural effusion. Chinese Community Doctors, 14, 82.
  32. Yan J, Jiang Y, Xu HL (2012). The research progress of endostar in the treatment of malignant Ascite/pleural effusion. Practical J Cancer, 5, 538-9.
  33. Yang K (2013). Clinical study of recombinant human endostatin combined with nadaplatin for treatment of malignant pleural effusion. Acta Academiae Medicinae Xuzhou, 33, 891-3.
  34. Yang Y, Lin TY, Chao GM (2013). Shortterm and longterm efficacy of endostar combined with cisplatinum malignant pleural effusion of non-small cell lung cancer. China Pharmaceuticals, 22, 21-2.
  35. Yao QH, Lin QF, Liu SP, et al (2012). Efficacy of intrapleural infusion of endostar combined with nedaplatin in the treatment of malignant pleural effusion. J Basic Clinical Oncol, 25, 492-4.
  36. Yue GJ, Bo YJ, Ma H, et al (2014). Analysis of efficacy and security on endostar combined with cisplatin in the treatment of nonsmall cell lung cancer bloody pleural effusion. Modern Diagnosis Treatment, 11, 2478-80.
  37. Zhao WY, Chen DY, Chen JH, et al (2014). Effects of intracavitary administration of endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 70, 623-8. https://doi.org/10.1007/s12013-014-9965-9
  38. Zhen LP, Xia LP, Xu TF, et al (2011). Cinical efficacy of DDP combined endostar by sequential perfusion and effect on VEGF expression in malignant ascite/pleural effusion. Practical Preventive Mxlicine, 8, 1494-6.
  39. Zhen QH, Hu W, Liao XF, et al (2013). A comparision between intrapleural injection of cisplatin combined with endostar and cisplatin alone in the treatment for malignant pleural effusion. J Chinese Oncol, 5, 386-9.
  40. Zhou WB, Bai M, Jin Y (2009). Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis, 13, 381-6.